|Bid||66.16 x 900|
|Ask||68.70 x 900|
|Day's range||66.75 - 69.17|
|52-week range||41.85 - 73.99|
|Beta (5Y monthly)||0.99|
|PE ratio (TTM)||16.54|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Thank you, Regina, and my thanks to each of you for joining us to discuss Henry Schein's results for the second quarter of 2020. With me on the call today are Stanley Bergman, chairman of the board and chief executive officer at Henry Schein; and Steven Paladino, executive vice president and chief financial officer. As you know, risks and uncertainties involved in the company's business may affect the matters referred to in forward-looking statements.
Henry Schein (HSIC) sees dismal segmental performance in Q2 due to disruptions resulting from the coronavirus pandemic.
Dental product company Henry Schein (NASDAQ:HSIC) saw sales sink 31% in the second quarter as Americans canceled dental appointments and stayed home to prevent the spread of Covid-19. Chief Executive Officer Stanley Bergman said sales improved compared to their original expectations over the quarter as dental and medical offices went back to work faster than anticipated. “We remain cautiously optimistic about the immediate future while closely monitoring global diagnosed COVID-19 cases and the potential impact on customer activity, and focusing on cash management," Bergman said.